In the first half of 2025, Abbott Laboratories really held its ground in the US medical device scene, making solid progress with its main products. A company called GlobalData, which knows its stuff about data and analytics, noted that some of Abbott’s high-volume products saw a drop in average selling prices (ASP) in the first half of the year compared to the same time last year. But, their top revenue products kept those ASPs rock steady between 2024 and 2025, hinting that Abbott’s pretty good at dodging those economic curveballs, like shifting tariff rules.
Checking out Abbott’s busy products, there’s a story there. The big sellers of 2024 got a little bump in ASPs, whereas the 2025 leaders stayed the same or even dipped slightly. Might be because US healthcare buyers are tweaking their game, maybe thanks to changing health priorities and watching their pennies.
Abbott’s latest financial report shows they had a robust start to 2025, with a 14.8% jump in US medical device sales compared to the first half of 2024. GlobalData’s recent figures highlight that several key products like MitraClip, Ensite X, and Tactiflex are still going strong. In the US heart-related market, Abbott’s got about 18% of the share, according to GlobalData.
On the diagnostics side, Abbott’s year-over-year sales took a slight dip in the second quarter of 2025, especially in quick and point-of-care tests. This seems tied to a drop in demand for Covid-19 tests, which were once flying off the shelves. This change in demand could explain what’s going on with some of Abbott’s hot-selling products.
